Patent details

EP4228753 Title: CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Unitary Effect

Unitary Effect Requested:
Yes
Unitary Effect Request Filing Date:
06/08/2025
Unitary Effect Status:
Unitary Effect Registered
Request Unitary Effect Accepted:
18/08/2025
Unitary Effect Date:
30/07/2025
Unitary Effect Registration Date:
18/08/2025
Request Unitary Effect Rejected:
Unitary Effect Re-establishment of rights Filing Date:
Unitary Effect Re-establishment of rights EPO Decision :
Unitary Effect Re-establishment of rights EPO Decision Date:
Unitary Effect Request Withdrawal Date:
Unitary Effect request has been accepted, please see the UPP register at the EPO for up-to-date information
UPP register:
EP4228753
SPC Number:
Creation Date:

Basic Information

Publication number:
EP4228753
WO Application Number:
CN2021123387
Type:
European Patent Granted for NL
Status:
Unitary Effect Registered
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP21798552.2
WO Publication Number:
WO2022078352
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
China (CN)
Publications:

Dates

Filing date:
13/10/2021
Grant date:
30/07/2025
EP Publication Date:
23/08/2023
WO Publication Date:
21/04/2022
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
30/07/2025
EP B1 Publication Date:
30/07/2025
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
12/10/2041
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
30/07/2025
 
 

 

Name:
Qilu Regor Therapeutics Inc.
Address:
Building 10 No. 1206, Zhangjiang Road, Shanghai 201210, China (CN)

Inventor

1

Name:
ZHONG, Wenge
Address:
Thousand Oaks, California 91362, United States of America (US)

2

Name:
GUO, Wei
Address:
Shanghai 201210, China (CN)

3

Name:
LI, Zheng Jane
Address:
Sherman, CT 06784, United States of America (US)

4

Name:
JIANG, Xiawei
Address:
Hangzhou Bay New Area Ningbo, Zhejiang 315336, China (CN)

5

Name:
CHEN, Pengyuan
Address:
Hangzhou Bay New Area Ningbo, Zhejiang 315336, China (CN)

Priority

Priority Patent Number:
PCT/CN2020/120814
Priority Date:
14/10/2020
Priority Country:
World Intellectual Property Office (WIPO) (WO)

Classification

IPC or IDT classification:
A61P 3/10; C07D 405/14; A61K 31/4439;

Publication

Bulletin

1

Bulletin Heading:
UP1
Journal edition number:
38/25
Publication date:
17/09/2025
Description:
European patents with registered Unitary Effect

2

Bulletin Heading:
EP2
Journal edition number:
31/25
Publication date:
30/07/2025
Description:
European patents granted for the Netherlands

European Patent Bulletin

1

Issue number:
202538
Publication date:
17/09/2025
Description:
Unitary Effect Request Acceptance

2

Issue number:
202537
Publication date:
10/09/2025
Description:
Unitary Effect Request Receipt

3

Issue number:
202531
Publication date:
30/07/2025
Description:
Grant (B1)

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type